On May 14, 2025, Cantor Fitzgerald reiterated its "Overweight" rating for NeuroPace (NPCE, Financial). The firm, led by analyst Ross Osborn, also maintained its price target for NPCE at $17.00, unchanged from its previous target.
NeuroPace (NPCE, Financial), a company trading on the NASDAQ, continues to attract attention in the stock market, with Cantor Fitzgerald's endorsement highlighting confidence in its market position. The consistent price target indicates stability in the firm's expectations for NPCE's stock performance.
The price target set by Cantor Fitzgerald reflects their analysis of NPCE’s potential in the market, emphasizing the firm's belief in NeuroPace's strategic positioning and future prospects. Investors and market watchers will be keeping a close eye on NeuroPace (NPCE, Financial) following this reiteration.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for NeuroPace Inc (NPCE, Financial) is $17.67 with a high estimate of $20.00 and a low estimate of $17.00. The average target implies an upside of 18.49% from the current price of $14.91. More detailed estimate data can be found on the NeuroPace Inc (NPCE) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, NeuroPace Inc's (NPCE, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for NeuroPace Inc (NPCE, Financial) in one year is $9.28, suggesting a downside of 37.76% from the current price of $14.91. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the NeuroPace Inc (NPCE) Summary page.
